PCN103 REAL-WORLD COSTS AND HEALTHCARE RESOURCE UTILIZATION (HRU) PATTERNS IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA (R/R-MCL) PATIENTS POST-IBRUTINIB FAILURE
نویسندگان
چکیده
منابع مشابه
Simulation Model of Ibrutinib in Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL).
(lowest vs highest; HR 1.12, 95%CI 1.07-1.16), grade (high vs low, HR 1.72, 95%CI 1.63-1.82), tumour size (2-5 cm vs 1-2 cm; HR 1.46, 95%CI 1.40-1.51), and a higher number of positive lymph nodes (1-3 vs 0; HR 1.40, 95%CI 1.34-1.46 and > 10 vs 0; HR 3.19, 95%CI 3.00-3.39) influenced death, all to a larger extent than surgical volume did. ConClusions: In the Netherlands, surgical hospital volume...
متن کاملComplications, costs And Resource Utilization in Real-World Complex Abdominal Wall Reconstruction Patients.
• The CAWR patient population was defined by adopting the approach described in DeNoto et al, 20135 • A cohort of patients with CAWR during inpatient stays between1/1/08 and 6/30/11 (Index event) were followed for 12 months. • Related complications, returns for facility-based care and related costs were evaluated during the index hospitalization and for 30-60-90-365 days after discharge. • Insu...
متن کاملIbrutinib for a Paraneoplastic Polyneuropathy in Mantle Cell Lymphoma
Mantle cell lymphoma is a rare and aggressive form of non-Hodgkin lymphoma. Paraneoplastic disease with central nervous system involvement is a rare complication. Immunosuppression for the paraneoplastic features and chemotherapy for the underlying malignancy are described treatments but benefits are often short-lived because of co-morbid complications and disease resistance. This report descri...
متن کاملHealthcare Resource Utilization in Patients Receiving Omalizumab for Allergic Asthma in a Real-World Setting
INTRODUCTION Inadequately controlled asthma is associated with increased healthcare resource utilization. The eXpeRience registry was initiated to evaluate real-world outcomes in patients receiving omalizumab for uncontrolled persistent allergic asthma. The current analysis of data from the eXpeRience registry focuses on healthcare resource utilization and on absences from work or school. MET...
متن کاملIbrutinib for the treatment of mantle cell lymphoma.
Mantle cell lymphoma (MCL) is a rare and aggressive form of non-Hodgkin's lymphoma. It can follow a heterogeneous clinical course but generally patients relapse early after standard immunochemotherapy regimens and develop resistance to subsequent therapies. For younger patients, intensive approaches followed by autologous stem cell transplantation offer excellent long-term disease control but w...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Value in Health
سال: 2019
ISSN: 1098-3015
DOI: 10.1016/j.jval.2019.04.227